The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis

• DOI: 10.1186/s12931-018-0732-0
• Publication Date: 2018-02-06T08:37:43Z
• Authors: Omar S. Usmani; Martyn F. Biddisc...; Shuying Yang; Sally Meah; Eunice Oballa; Juliet K. Simpson; William A. Fahy; Richard P. Marshall; Pauline T. Lukey; Toby M. Maher
• Keywords: Dispersity; Crossover study; Metered-dose inhaler; Nebulizer; Penetration (warfare)

Our aim was to investigate total and regional lung delivery of salbutamol in subjects with idiopathic pulmonary fibrosis (IPF). The TOPICAL study a 4-period, partially-randomised, controlled, crossover four aerosolised approaches IPF subjects. Nine were randomised receive 99mTechnetium-labelled monodisperse (1.5 μm or 6 μm; periods 1 2). Subjects also received radio-labelled using polydisperse nebuliser (period 3) unlabelled (400 μg) pressurized metered dose inhaler volumatic spacer (pMDI; period 4). Small particles μm) achieved significantly better deposition (TLD, mean % ± SD) than larger (6 μm), where nebulisation poor; 64.93 10.72; 50.46 17.04; 8.19 7.72, respectively). penetration (mean showed similar the small particles; PI 0.8 0.16, 0.49 0.21, 0.73 0.19, respectively. Higher dose-normalised plasma levels observed following 1.5 particles, compared pMDI inhalation, while lowest nebulisation. data is first systematic investigation inhaled drug fibrotic disease. We provide evidence that drugs can be optimised reach peripheral areas active scarring occurs IPF. This trial registered on clinicaltrials.gov ( NCT01457261 ).